Drugs for benign prostatic hypertrophy

Manasi Jiwrajka; William Yaxley; Sachinka Ranasinghe; Marlon Perera; Matthew J Roberts; John Yaxley

doi:10.18773/austprescr.2018.045

Drugs for benign prostatic hypertrophy

Aust Prescr. 2018 Oct;41(5):150-153. doi: 10.18773/austprescr.2018.045. Epub 2018 Oct 1.

Authors

Manasi Jiwrajka^{1

2

3}, William Yaxley^{1

2

3}, Sachinka Ranasinghe^{1

2

3}, Marlon Perera^{1

2

3}, Matthew J Roberts^{1

2

3}, John Yaxley^{1

2

3}

Affiliations

¹ Royal Brisbane and Women's Hospital.
² Faculty of Medicine, University of Queensland, Brisbane.
³ Department of Surgery, Austin Health, University of Melbourne.

Abstract

Benign prostatic hyperplasia is a common condition. It can cause problems with urine storage and voiding, and the severity of symptoms may be unrelated to the size of the prostate

When drug treatment is required, benign prostatic hyperplasia can be managed with monotherapy or combination therapy. Most patients are managed with selective alpha blockers

Patients with larger prostate volumes may benefit from a 5-alpha-reductase inhibitor, usually in combination with an alpha blocker

Keywords: 5-alpha-reductase inhibitors; alpha blockers; benign prostatic hyperplasia.

Publication types

Review